dihydrolipoic acid has been researched along with dinoprostone in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ho, SY; Ho, YS; Lai, CS; Liu, HI; Pan, MH; Tai, C; Wang, YJ | 1 |
| Bourdette, DN; Carr, DW; Regan, JW; Salinthone, S; Schillace, RV; Tsang, C | 1 |
2 other study(ies) available for dihydrolipoic acid and dinoprostone
| Article | Year |
|---|---|
Dihydrolipoic acid inhibits skin tumor promotion through anti-inflammation and anti-oxidation.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cyclooxygenase 2; Dinoprostone; Disease Models, Animal; Drug Interactions; Female; Inflammation; Lipopolysaccharides; Mice; Nitric Oxide Synthase Type II; Nitrites; Oxidation-Reduction; Skin Neoplasms; Tetradecanoylphorbol Acetate; Thioctic Acid | 2007 |
Lipoic acid stimulates cAMP production via G protein-coupled receptor-dependent and -independent mechanisms.
Topics: Adenylyl Cyclase Inhibitors; Adenylyl Cyclases; Calcium Signaling; Cyclic AMP; Dinoprostone; Egtazic Acid; HEK293 Cells; Humans; Killer Cells, Natural; Leukocytes, Mononuclear; Receptors, G-Protein-Coupled; Receptors, Prostaglandin E, EP2 Subtype; Receptors, Prostaglandin E, EP4 Subtype; Thioctic Acid | 2011 |